G3: Genes, Genomes, Genetics
Authors
Kristina K Gagalova, Justin GA Whitehill, Luka Culibrk, Diana Lin, Véronique Lévesque-Tremblay, Christopher I Keeling, Lauren Coombe, Macaire MS Yuen, Inanç Birol, Jörg Bohlmann, Steven JM Jones
Publication Abstract

The highly diverse insect family of true weevils, Curculionidae, includes many agricultural and forest pests. Pissodes strobi, commonly known as the spruce weevil or white pine weevil, is a major pest of spruce and pine forests in North America. P. strobi larvae feed on the apical shoots of young trees, causing stunted growth and can destroy regenerating spruce or pine forests. Here we describe the nuclear and mitochondrial P. strobi genomes and their annotations, as well as the genome of an apparent Wolbachia endosymbiont. We report a substantial expansion of the weevil nuclear genome, relative to other Curculionidae species, possibly driven by an abundance of Class II DNA transposons. The endosymbiont observed belongs to a group (supergroup A) of Wolbachia species that generally form parasitic relationships with their arthropod host.

Cancers
Authors
Dean A Regier, Brandon Chan, Sarah Costa, David W Scott, Christian Steidl, Joseph M Connors, Aly Karsan, Marco A Marra, Robert Kridel, Ian Cromwell, Samantha Pollard
Publication Abstract

Background: Classifying diffuse large B-cell lymphoma (DLBCL) into cell-of-origin (COO) subtypes could allow for personalized cancer control. Evidence suggests that subtype-guided treatment may be beneficial in the activated B-cell (ABC) subtype of DLBCL, among patients under the age of 60.

Methods: We estimated the cost-effectiveness of age- and subtype-specific treatment guided by gene expression profiling (GEP). A probabilistic Markov model examined costs and quality-adjusted life-years gained (QALY) accrued to patients under GEP-classified COO treatment over a 10-year time horizon. The model was calibrated to evaluate the adoption of ibrutinib as a first line treatment among patients under 60 years with ABC subtype DLBCL. The primary data source for efficacy was derived from published estimates of the PHOENIX trial. These inputs were supplemented with patient-level, real-world data from BC Cancer, which provides comprehensive cancer services to the population of British Columbia.

Results: We found the cost-effectiveness of GEP-guided treatment vs. standard care was $77,806 per QALY (24.3% probability of cost-effectiveness at a willingness-to-pay (WTP) of $50,000/QALY; 53.7% probability at a WTP of $100,000/QALY) for first-line treatment. Cost-effectiveness was dependent on assumptions around decision-makers' WTP and the cost of the assay.

Conclusions: We encourage further clinical trials to reduce uncertainty around the implementation of GEP-classified COO personalized treatment in this patient population.

Cell Reports
Authors
Fraser D Johnson, et al. (including Gregg B Morin).
Publication Abstract

Phenotype-based screening can identify small molecules that elicit a desired cellular response, but additional approaches are required to characterize their targets and mechanisms of action. Here, we show that a compound termed LCS3, which selectively impairs the growth of human lung adenocarcinoma (LUAD) cells, induces oxidative stress. To identify the target that mediates this effect, we use thermal proteome profiling (TPP) and uncover the disulfide reductases GSR and TXNRD1 as targets. We confirm through enzymatic assays that LCS3 inhibits disulfide reductase activity through a reversible, uncompetitive mechanism. Further, we demonstrate that LCS3-sensitive LUAD cells are sensitive to the synergistic inhibition of glutathione and thioredoxin pathways. Lastly, a genome-wide CRISPR knockout screen identifies NQO1 loss as a mechanism of LCS3 resistance. This work highlights the ability of TPP to uncover targets of small molecules identified by high-throughput screens and demonstrates the potential therapeutic utility of inhibiting disulfide reductases in LUAD.

Nature Cancer
Authors
Laura M Richards, Owen KN Whitley, Graham MacLeod, Florence MG Cavalli, Fiona J Coutinho, Julia E Jaramillo, Nataliia Svergun, Mazdak Riverin, Danielle C Croucher, Michelle Kushida, Kenny Yu, Paul Guilhamon, Naghmeh Rastegar, Moloud Ahmadi, Jasmine K Bhatti, Danielle A Bozek, Naijin Li, Lilian Lee, Clare Che, Erika Luis, Nicole I Park, Zhiyu Xu, Troy Ketela, Richard A Moore, Marco A Marra, Julian Spears, Michael D Cusimano, Sunit Das, Mark Bernstein, Benjamin Haibe-Kains, Mathieu Lupien, H Artee Luchman, Samuel Weiss, Stephane Angers, Peter B Dirks, Gary D Bader, Trevor J Pugh
Publication Abstract

Glioblastomas harbor diverse cell populations, including rare glioblastoma stem cells (GSCs) that drive tumorigenesis. To characterize functional diversity within this population, we performed single-cell RNA sequencing on >69,000 GSCs cultured from the tumors of 26 patients. We observed a high degree of inter- and intra-GSC transcriptional heterogeneity that could not be fully explained by DNA somatic alterations. Instead, we found that GSCs mapped along a transcriptional gradient spanning two cellular states reminiscent of normal neural development and inflammatory wound response. Genome-wide CRISPR-Cas9 dropout screens independently recapitulated this observation, with each state characterized by unique essential genes. Further single-cell RNA sequencing of >56,000 malignant cells from primary tumors found that the majority organize along an orthogonal astrocyte maturation gradient yet retain expression of founder GSC transcriptional programs. We propose that glioblastomas grow out of a fundamental GSC-based neural wound response transcriptional program, which is a promising target for new therapy development.

American Journal of Medical Genetics Part A
Authors
Pierre K Boerkoel, Katherine Dixon, Carrie Fitzsimons, Yaoqing Shen, Stephanie Huynh, Kamilla Schlade-Bartusiak, Luka Culibrk, Simon Chan, Cornelius F Boerkoel, Steven JM Jones, Hui-Lin Chin
Publication Abstract

Microphthalmia, anophthalmia, and coloboma (MAC) are a heterogeneous spectrum of anomalous eye development and degeneration with genetic and environmental etiologies. Structural and copy number variants of chromosome 13 have been implicated in MAC; however, the specific loci involved in disease pathogenesis have not been well-defined. Herein we report a newborn with syndromic degenerative anophthalmia and a complex de novo rearrangement of chromosome 13q. Long-read genome sequencing improved the resolution and clinical interpretation of a duplication-triplication/inversion-duplication (DUP-TRP/INV-DUP) and terminal deletion. Sequence features at the breakpoint junctions suggested microhomology-mediated break-induced replication (MMBIR) of the maternal chromosome as the origin. Comparing this rearrangement to previously reported copy number alterations in 13q, we refine a putative dosage-sensitive critical region for MAC that might provide new insights into its molecular etiology.

European Journal of Haemotology
Authors
Ryan J Stubbins, Maria Stamenkovic, Claudie Roy, Judith Rodrigo, Shanee Chung, Florian C Kuchenbauer, Kevin A Hay, Jennifer White, Yasser Abou Mourad, Maryse M Power, Sujaatha Narayanan, Donna L Forrest, Cynthia L Toze, Heather J Sutherland, Stephen H Nantel, Thomas J Nevill, Aly Karsan, Kevin W Song, David S Sanford
Publication Abstract

Objectives: Acute myeloid leukaemia (AML) is a disease of older adults, who are vulnerable to socioeconomic factors. We determined AML incidence in older adults and the impact of socioeconomic factors on outcomes.

Methods: We included 3024 AML patients (1996-2016) identified from a population-based registry.

Results: AML incidence in patients ≥60 years increased from 11.01 (2001-2005) to 12.76 (2011-2016) per 100,000 population. Amongst 879 patients ≥60 years in recent eras (2010-2016), rural residents (<100,000 population) were less likely to be assessed by a leukaemia specialist (39% rural, 47% urban, p=0.032); no difference was seen for lower (43%, quintile 1-3) versus higher (47%, quintile 4-5) incomes (p=0.235). Similar numbers received induction chemotherapy between residence (16% rural, 18% urban, p=0.578) and incomes (17% lower, 17% high, p=1.0). Differences between incomes were seen for hypomethylating agent treatment (14% low, 20% high, p=0.041); this was not seen for residence (13% rural, 18% urban, p=0.092). Amongst non-adverse karyotype patients ≥70 years, 2-year overall survival was worse for rural (5% rural, 12% urban, p=0.006) and lower income (6% low, 15% high, p=0.017) patients.

Conclusions: AML incidence in older adults is increasing, and outcomes are worse for older rural and low-income residents; these patients face treatment barriers.

Proceedings of the National Academy of Sciences of the United States of America
Authors
Harris A Lewin, et al., (including Steven JM Jones)

BMC Genomics
Authors
Chenkai Li, Darcy Sutherland, S Austin Hammond, Chen Yang, Figali Taho, Lauren Bergman, Simon Houston, René L Warren, Titus Wong, Linda MN Hoang, Caroline E Cameron, Caren C Helbing, Inanc Birol
Publication Abstract

Background: Antibiotic resistance is a growing global health concern prompting researchers to seek alternatives to conventional antibiotics. Antimicrobial peptides (AMPs) are attracting attention again as therapeutic agents with promising utility in this domain, and using in silico methods to discover novel AMPs is a strategy that is gaining interest. Such methods can sift through large volumes of candidate sequences and reduce lab screening costs.

Results: Here we introduce AMPlify, an attentive deep learning model for AMP prediction, and demonstrate its utility in prioritizing peptide sequences derived from the Rana [Lithobates] catesbeiana (bullfrog) genome. We tested the bioactivity of our predicted peptides against a panel of bacterial species, including representatives from the World Health Organization's priority pathogens list. Four of our novel AMPs were active against multiple species of bacteria, including a multi-drug resistant isolate of carbapenemase-producing Escherichia coli.

Conclusions: We demonstrate the utility of deep learning based tools like AMPlify in our fight against antibiotic resistance. We expect such tools to play a significant role in discovering novel candidates of peptide-based alternatives to classical antibiotics.

Cell Reports Methods
Authors
Vincent CT Hanlon, Daniel D Chan, Zeid Hamadeh, Yanni Wang, Carl-Adam Mattsson, Diana CJ Spierings, Robin JN Coope, Peter M Lansdorp
Publication Abstract

Single-cell Strand-seq generates directional genomic information to study DNA repair, assemble genomes, and map structural variation onto chromosome-length haplotypes. We report a nanoliter-volume, one-pot (OP) Strand-seq library preparation protocol in which reagents are added cumulatively, DNA purification steps are avoided, and enzymes are inactivated with a thermolabile protease. OP-Strand-seq libraries capture 10%-25% of the genome from a single-cell with reduced costs and increased throughput.

European Urology
Authors
Vanessa Di Lalla, Michael J Kucharczyk, Alexander W Wyatt, Felix Y Feng, Stephan Probst, Gwenaelle Gravis, Jonathan So, Fred Saad, Tamim Niazi
Publication Abstract

Tumor biology may play an important role as an effective predictive biomarker that is complementary to functional imaging for metastatic hormone-sensitive prostate cancer.

Back to top